+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Skeletal Dysplasia Market 2020-2026

  • PDF Icon


  • July 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5148116
Global Skeletal Dysplasia Market Size, Share & Trends Analysis Report By Type (Achondroplasia, Thanatophoric dysplasia, Hypochondroplasia, and Others), By Treatment (Medications, Therapy, and Others), Forecast Period 2020-2026.

The global skeletal dysplasia market is anticipated to grow at a modest growth rate during the forecast period. Skeletal dysplasia contains a group of conditions that are associated with bone deformities. The recent surge in the initiatives across the globe focusing on the development of various novel drugs for the treatment of skeletal dysplasia disorder is anticipated to contribute significantly to the growth of the skeletal dysplasia market.

The global skeletal dysplasia market is segmented on the basis of type and treatment. Based on the type, the market is sub-segmented into achondroplasia, thanatophoric dysplasia, hypochondroplasia, and others. Further, based on the treatment, the market is sub-segmented into medications, therapy, and others. The other segment contains surgery that is performed to correct the deformities in skeletal dysplasia disorder patients. Moreover, the global skeletal dysplasia market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. Europe is expected to hold a significant market share during the forecast period. The rise in skeletal dysplasia market is due to the increased adoption of surgical methods for the treatment of various skeletal dysplasia disorders in the European region.

The key players of the global skeletal dysplasia market include Alexion Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Ipsen Pharma, Merck KGaA, Regeneron Pharmaceuticals Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger & acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

For instance, in October 2019, Ipsen Pharma through its subsidiary Clementia Pharmaceuticals has entered into a definitive license agreement with Blueprint Medicines Corp. for the development and commercialization of BLU-782, an oral, highly selective investigational ALK2 inhibitor. These inhibitors are indicated for the treatment of fibrodysplasia ossificans progressiva (FOP) which is a type of skeletal dysplasia disorder. The agreement is expected to enhance Ipsen Pharma’s Rare Diseases portfolio as well as advance the Blueprint Medicines’ goal of rapidly and efficiently developing BLU-782 as a potential treatment for patients with FOP.

Research Methodology:

The market study of the global skeletal dysplasia market is incorporated by extensive primary and secondary research. Secondary research has been conducted to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for government organizations, pharmaceutical drug manufacturers, research institutions, health insurance companies, and other related industries for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Global Skeletal Dysplasia Market Research and Analysis by Type
2. Global Skeletal Dysplasia Market Research and Analysis by Treatment

The Report Covers:
  • Comprehensive research methodology of the global skeletal dysplasia market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global skeletal dysplasia market.
  • Insights about market determinants which are stimulating the global skeletal dysplasia market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Business Functions and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Alexion Pharmaceuticals, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. BioMarin Pharmaceutical Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Ipsen Pharma Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Merck KGaA Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. Regeneron Pharmaceuticals Inc. Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. Global Skeletal dysplasia Market by Type
5.1.1. Achondroplasia
5.1.2. Thanatophoric dysplasia
5.1.3. Hypochondroplasia
5.1.4. Others
5.2. Global Skeletal dysplasia Market by Treatment
5.2.1. Medications
5.2.2. Therapy
5.2.3. Others (Surgery)
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Alexion Pharmaceuticals, Inc.
7.2. Amgen Inc.
7.3. Ascendis Pharma A/S
7.4. BioMarin Pharmaceutical Inc.
7.5. Invitae Corp.
7.6. Ipsen Pharma
7.7. Merck KGaA
7.8. Novartis AG
7.9. Novo Nordisk A/S
7.10. Pfizer Inc.
7.11. Regeneron Pharmaceuticals Inc.
7.12. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Ascendis Pharma A/S
  • BioMarin Pharmaceutical Inc.
  • Invitae Corp.
  • Ipsen Pharma
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.